Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4133590 | 1.00 | PARP1 (0.36) | PARP1MAOBTSHRCA1CA2 | |
| SCHEMBL160705 | 0.84 | PARP1 (0.40) | PARP1MAOBTSHRCA1CA2 | |
| SCHEMBL29385098 | 0.84 | PARP1 (0.40) | PARP1MAOBTSHRCA1CA2 | |
| SCHEMBL9420914 | 0.82 | PARP1 (0.39) | PARP1MAOBTSHRCA1CA2 | |
| Methane SCHEMBL27705727 | 0.82 | PARP1 (0.39) | PARP1MAOBTSHRCA1CA2 | |
| Lithium SCHEMBL9420915 | 0.82 | PARP1 (0.39) | PARP1MAOBTSHRCA1CA2 | |
| SCHEMBL27701784 | 0.82 | PARP1 (0.39) | PARP1MAOBTSHRCA1CA2 | |
| Iodide SCHEMBL28897108 | 0.82 | PARP1 (0.39) | PARP1MAOBTSHRCA1CA2 | |
| Water SCHEMBL27782064 | 0.82 | PARP1 (0.39) | PARP1MAOBTSHRCA1CA2 | |
| SCHEMBL15638199 | 0.78 | PARP1 (0.36) | PARP1MAOBTSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-61018734-A | — | — | None | — | — | JP | disclosed |
| EP-1896391-B1 | COMBRETASTATIN ANALOGS WITH TUBULIN BINDING ACTIVITY | UNIV BAYLOR (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8394859-B2 | Combretastatin analogs with tubulin binding activity | BAYLOR UNIVERSITY (US) | 2013-03-12 | — | — | US | disclosed |
| US-20090075943-A1 | Combretastatin Analogs with Tubulin Binding Activity | BAYLOR UNIVERSITY | 2009-03-19 | — | — | US | disclosed |
| US-7429681-B2 | Combretastatin analogs with tubulin binding activity | BAYLOR UNIVERSITY (US) | 2008-09-30 | — | — | US | disclosed |
| EP-1896391-A2 | COMBRETASTATIN ANALOGS WITH TUBULIN BINDING ACTIVITY | Baylor University (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20060293394-A1 | Combretastatin analogs with tubulin binding activity | BAYLOR UNIVERSITY | 2006-12-28 | — | — | US | disclosed |
| WO-2006138427-A2 | COMBRETASTATIN ANALOGS WITH TUBULIN BINDING ACTIVITY | BAYLOR UNIVERSITY (US) | 2006-12-28 | — | — | WO | disclosed |
| JP-S6118734-A | PRODUCTION OF LIGNAN | TSUMURA JUNTENDO INC | 1986-01-27 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293394-A1 | Combretastatin analogs with tubulin binding activity | TUBB, TUBB3, TUBB1 | PARP1 207/4885MAOB 3732/4885TSHR 3943/4885 |
| US-20090075943-A1 | Combretastatin Analogs with Tubulin Binding Activity | TUBB, TUBB3, TUBB1 | PARP1 207/4885MAOB 3732/4885TSHR 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.